The global vagus nerve stimulators market is estimated to be valued at USD 607.2 MN in 2024 and is expected to exhibit a CAGR of 9.7% during the forecast period (2024-2031). The vagus nerve is the longest cranial nerve that interacts with several organs of the body including the heart. Vagus nerve stimulation or VNS involves delivering electrical pulses to the vagus nerve using an implantable medical device called a vagus nerve stimulator. This therapy relies on the principle that stimulating the vagus nerve can help regulate abnormal brain activity and seizure control. Vagus nerve stimulators are used as an adjunctive therapy for reducing the frequency and severity of seizures in patients with epilepsy whose conditions are not fully controlled by medications. The therapeutic potential of VNS is being explored for treating other neurological and psychiatric disorders such as depression, Alzheimer's disease, and migraine too.

Market Dynamics:

The global vagus nerve stimulators market is driven by the rising prevalence of epilepsy and other neurological disorders, growing awareness and acceptance of VNS therapy, and favorable reimbursement policies. However, high costs associated with VNS devices and surgeries coupled with adverse effects and complications associated with stimulation of the vagus nerve act as key restraints for the market growth. Development of innovative stimulation devices with improved features and expanding therapeutic applications of VNS present high-impact rendering opportunities. Stakeholders are investing in research trials to evaluate the efficacy of VNS in conditions such as treatment-resistant depression, rheumatoid arthritis, and heart failure.

Key Features of the Study:

• This report provides an in-depth analysis of the global vagus nerve stimulators market, and provides market size (USD MN) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year.
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global vagus nerve stimulators market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include LivaNova PLC, electroCore Inc., SetPoint Medical Corporation, Beijing PINS Medical Co. Ltd., Parasym Ltd., Nervana LLC, tVNS Technologies GmbH, BioControl Medical, NeurAxis Inc., Soterix Medical Inc., MicroTransponder Inc., Boston Scientific Corporation, Cyberonics Inc., EnteroMedics Inc., ReShape Lifesciences Inc., and Cerbomed GmbH.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global vagus nerve stimulators market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global vagus nerve stimulators market.

Market Segmentation

• Product Type:
  • Implantable Devices
  • External Devices 
• Application:
  • Epilepsy
  • Depression & Anxiety
  • Migraine
  • Others 
• Material Type:
  • Ceramics
  • Metallics
  • Polymerics
• End User:
  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers
  • Others
• Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • LivaNova PLC
  • electroCore Inc.
  • SetPoint Medical Corporation
  • Beijing PINS Medical Co. Ltd.
  • Parasym Ltd.
  • Nervana LLC
  • tVNS Technologies GmbH
  • BioControl Medical
  • NeurAxis Inc.
  • Soterix Medical Inc.
  • MicroTransponder Inc.
  • Boston Scientific Corporation
  • Cyberonics Inc.
  • EnteroMedics Inc.
  • ReShape Lifesciences Inc.
  • Cerbomed GmbH